Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85


Histone deacetylase inhibitors as potential therapeutic approaches for chordoma: an immunohistochemical and functional analysis.

Scheipl S, Lohberger B, Rinner B, Froehlich EV, Beham A, Quehenberger F, Lazáry A, Pal Varga P, Haybaeck J, Leithner A, Liegl B.

J Orthop Res. 2013 Dec;31(12):1999-2005. doi: 10.1002/jor.22447. Epub 2013 Jul 24.


Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.

Niegisch G, Knievel J, Koch A, Hader C, Fischer U, Albers P, Schulz WA.

Urol Oncol. 2013 Nov;31(8):1770-9. doi: 10.1016/j.urolonc.2012.06.015. Epub 2012 Sep 1.


Modulation of radiation response by histone deacetylase inhibition.

Chinnaiyan P, Vallabhaneni G, Armstrong E, Huang SM, Harari PM.

Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):223-9.


Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo.

Hrzenjak A, Moinfar F, Kremser ML, Strohmeier B, Petru E, Zatloukal K, Denk H.

Mol Cancer. 2010 Mar 4;9:49. doi: 10.1186/1476-4598-9-49.


Molecular sequelae of histone deacetylase inhibition in human malignant B cells.

Mitsiades N, Mitsiades CS, Richardson PG, McMullan C, Poulaki V, Fanourakis G, Schlossman R, Chauhan D, Munshi NC, Hideshima T, Richon VM, Marks PA, Anderson KC.

Blood. 2003 May 15;101(10):4055-62. Epub 2003 Jan 16.


HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA).

Mehdi O, Françoise S, Sofia CL, Urs G, Kevin Z, Bernard S, Igor S, Anabela CD, Dominique L, Eric M, Ali O.

Pancreatology. 2012 Mar-Apr;12(2):146-55. doi: 10.1016/j.pan.2012.02.013. Epub 2012 Feb 25.


Anticancer effects of the MHY218 novel hydroxamic acid-derived histone deacetylase inhibitor in human ovarian cancer cells.

Jeon HS, Ahn MY, Park JH, Kim TH, Chun P, Kim WH, Kim J, Moon HR, Jung JH, Kim HS.

Int J Oncol. 2010 Aug;37(2):419-28.


SAHA inhibits the growth of colon tumors by decreasing histone deacetylase and the expression of cyclin D1 and survivin.

Jin JS, Tsao TY, Sun PC, Yu CP, Tzao C.

Pathol Oncol Res. 2012 Jul;18(3):713-20. doi: 10.1007/s12253-012-9499-7. Epub 2012 Jan 20.


Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1.

Gui CY, Ngo L, Xu WS, Richon VM, Marks PA.

Proc Natl Acad Sci U S A. 2004 Feb 3;101(5):1241-6. Epub 2004 Jan 20.


Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.

Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, Qian X, Mills E, Berghs SC, Carey N, Finn PW, Collins LS, Tumber A, Ritchie JW, Jensen PB, Lichenstein HS, Sehested M.

Biochem J. 2008 Jan 15;409(2):581-9.


Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma.

Heider U, Kaiser M, Sterz J, Zavrski I, Jakob C, Fleissner C, Eucker J, Possinger K, Sezer O.

Eur J Haematol. 2006 Jan;76(1):42-50.


2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.

Mahboobi S, Sellmer A, Höcher H, Garhammer C, Pongratz H, Maier T, Ciossek T, Beckers T.

J Med Chem. 2007 Sep 6;50(18):4405-18. Epub 2007 Aug 11.


Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo.

Weichert W, Röske A, Niesporek S, Noske A, Buckendahl AC, Dietel M, Gekeler V, Boehm M, Beckers T, Denkert C.

Clin Cancer Res. 2008 Mar 15;14(6):1669-77. doi: 10.1158/1078-0432.CCR-07-0990.


Histone deacetylase inhibitors in the treatment of lymphoma.

Lemoine M, Younes A.

Discov Med. 2010 Nov;10(54):462-70. Review.


Synthesis and evaluation of aliphatic-chain hydroxamates capped with osthole derivatives as histone deacetylase inhibitors.

Huang WJ, Chen CC, Chao SW, Yu CC, Yang CY, Guh JH, Lin YC, Kuo CI, Yang P, Chang CI.

Eur J Med Chem. 2011 Sep;46(9):4042-9. doi: 10.1016/j.ejmech.2011.06.002. Epub 2011 Jun 12.


The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells.

Kerl K, Ries D, Unland R, Borchert C, Moreno N, Hasselblatt M, Jürgens H, Kool M, Görlich D, Eveslage M, Jung M, Meisterernst M, Frühwald M.

BMC Cancer. 2013 Jun 13;13:286. doi: 10.1186/1471-2407-13-286.


MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo.

Fournel M, Bonfils C, Hou Y, Yan PT, Trachy-Bourget MC, Kalita A, Liu J, Lu AH, Zhou NZ, Robert MF, Gillespie J, Wang JJ, Ste-Croix H, Rahil J, Lefebvre S, Moradei O, Delorme D, Macleod AR, Besterman JM, Li Z.

Mol Cancer Ther. 2008 Apr;7(4):759-68. doi: 10.1158/1535-7163.MCT-07-2026.


The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo.

Buckley MT, Yoon J, Yee H, Chiriboga L, Liebes L, Ara G, Qian X, Bajorin DF, Sun TT, Wu XR, Osman I.

J Transl Med. 2007 Oct 12;5:49.


Expression of ezrin, MMP-9, and COX-2 in 50 chordoma specimens: a clinical and immunohistochemical analysis.

Froehlich EV, Scheipl S, Lazàry A, Varga PP, Schmid C, Stammberger H, Beham A, Bodo K, Schroettner H, Quehenberger F, Windhager R, Liegl B, Leithner A.

Spine (Phila Pa 1976). 2012 Jun 1;37(13):E757-67. doi: 10.1097/BRS.0b013e31824782e1.


Supplemental Content

Support Center